Characterization of liver disease regression in murine models of liver fibrosis and portal hypertension
Characterization of toxin-induced mouse models of regressive liver disease, focusing on the detecting of a suitable therapeutic window during fibrosis and portal hypertension (PH) regression. C57BL/6JRj mice were studied when exposed to thioacetamide (TAA) or carbon tetrachloride (CCl 4 ) for 8 or 12 weeks (8w/12w) and after one/two (+R1/+R2) week(s) of TAA/CCl 4 -free regression. Healthy controls received NaCl or olive oil (OO). Primary readouts included liver fibrosis (collagen proportionate area, CPA), portal pressure (PP), serum transaminases and hepatic fibrosis-related gene expression. The diseased models (8wTAA/12wTAA/8wCCl 4 /12wCCl 4 ) showed significant fibrosis (CPA: 3.03/3.87/8.53/16.90%; vs. NaCl/OO: 0.87/1.15%) and PH (PP: 6.8/7.7/8.5/10.0 mmHg; vs. NaCl/OO: 5.5/5.1 mmHg). CPA significantly regressed in 8wTAA+R1 (2.60%; p = 0.01) and 12wCCl 4 +R1 (10.9%; p = 0.01), but not in 12wTAA+R1/8wCCl 4 +R1. CPA regression was significant in all +R2-groups ( p < 0.001) but not in 8wCCl 4 +R2 ( p = 0.30). Significant PP regression was found at 8wCCl 4 +R1 (5.8 mmHg; p = 0.004) and 12wCCl 4 +R1 (8.4 mmHg; p = 0.01), but not in the 8w/12w TAA models. All +R2-groups showed significant PP regression: 8wTAA+R2 (6.0 mmHg; p ≤ 0.001), 12wTAA+R2 (6.0 mmHg), 8wCCl 4 +R2 (6.0 mmHg, p = 0.004) and 12wCCl 4 +R2 (7.9 mmHg, p = 0.008). Serum AST/ALT levels at +R1/+R2 returned to levels of healthy controls. Hepatic Col1a1 and Timp1 gene expression peaked in 12w-groups and showed a gradual decrease at +R1/+R2: Col1a1 (12wTAA+R1/+R2: -14%/-29%, p = 0.002; 12wCCl 4 +R1/R2: -28%/-23%, p = 0.05) and Timp1 (12wTAA+R1/+R2: -41%/-61%, p ≤ 0.001; 12wCCl 4 +R1/R2: -43%/-40%, p ≤ 0.001). While liver disease regressed in all models/timepoints, both liver fibrosis (CPA) and PP remained increased in the 12wCCl 4 +R1/R2 settings – qualifying this model as suitable for pre-clinical testing of therapeutic strategies aimed at promoting liver fibrosis and PH regression.
Authors
- Stefan G. Kauschke (ORCID: https://orcid.org/0009-0007-4524-8578)
- Tatjana Stojaković (ORCID: https://orcid.org/0000-0001-9909-9749)
- Larissa Pfisterer
- Philipp Königshofer (ORCID: https://orcid.org/0000-0003-1279-1148)
- Ksenia Brusilovskaya (ORCID: https://orcid.org/0000-0002-8234-5875)
- Thomas Sorz (ORCID: https://orcid.org/0000-0002-9529-4851)
- Benedikt Simbrunner (ORCID: https://orcid.org/0000-0001-8181-9146)
- Vlad Țâru (ORCID: https://orcid.org/0000-0002-2313-7881)
- Philipp Schwabl (ORCID: https://orcid.org/0000-0002-7183-8076)
- Hubert Scharnagl (ORCID: https://orcid.org/0000-0002-2750-006X)
- Katharina Regnat
- Katharina Bonitz
- Oleksandr Petrenko (ORCID: https://orcid.org/0000-0002-8586-4910)
- Thomas Reiberger (ORCID: https://orcid.org/0000-0002-4590-3583)
- Benedikt Silvester Hofer (ORCID: https://orcid.org/0000-0003-3403-3372)
- Michael A Trauner (ORCID: https://orcid.org/0000-0002-1275-6425)
- Katharina Bareiner
- Kerstin Zinober (ORCID: https://orcid.org/0009-0004-0451-1593)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Austrian Academy of Sciences (AT)
- Medical University of Graz (AT)
- Graz University Hospital (AT)
- Christian Doppler Laboratory for Thermoelectricity (AT)
- CeMM Research Center for Molecular Medicine (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-06-14
- DOI
- https://doi.org/10.1038/s41598-026-54627-5
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boehringer Ingelheim
- Christian Doppler Forschungsgesellschaft